Zeinab Zeid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zeinab Zeid has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Adel Abdelsalam
Rheumatology and Immunology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Egypt
1 shared publication- Alaa Sabry
Mansoura Urology and Nephrology Center, Mansoura University, Mansoura, Egypt
1 shared publication - Dalia Abdellateif Abdelghany
Chest medicine department. Mansoura university. Egypt
1 shared publication Ehab Eltoraby
Rheumatology and Immunology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Egypt
1 shared publication- Mohamed Elgamal
Department of Chest Medicine, Mansoura University Hospitals, Faculty of Medicine, Mansoura University, Mansoura City 35516, Egypt
1 shared publication - Mohammed Kamal Nassar
Mansoura Nephrology and Dialysis Unit, Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt
1 shared publication
Latest Publications
- Open Access
Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study
Background and Objectives: In addition to a suboptimal and rapidly diminishing response to the coronavirus disease 2019 (COVID-19) vaccine, hemodialysis (HD) patients are at risk for developing a severe COVID-19 infection. In 2022, the combination of cilgavimab and tixagevimab (Evusheld, AstraZeneca) was approved for COVID-19 preexposure prophylaxis in high-risk groups. The purpose of this study was to evaluate the humoral response and short-term safety of this antibody combination in a group of HD patients. Materials and Methods: Seventy-three adult maintenance hemodialysis patients were recruited from a tertiary-care hospital for this double-blinded, non-randomized, placebo-controlled study. Patients were placed into two groups: the intervention group (n = 43) received a single 300 mg dosage of cilgavimab and tixagevimab, while the control group (n = 30) received a saline placebo. The titer of COVID-19-neutralizing antibodies was measured at baseline and after 1 and 6 months. The patients were evaluated for any drug-related adverse effects and monitored for six months for the emergence of any COVID-19-related events. Results: Patients in the intervention group were substantially older and had been on HD for longer (p = 0.002 and 0.006, respectively). The baseline antibody levels were higher in the Evusheld group. The antibody level in the intervention group increased significantly after 1 month and remained consistent for 6 months, whereas the antibody level in the control group fell significantly after 6 months during the study period (Wald χ2 = 30.620, p < 0.001). The drug-related adverse effects were modest and well-tolerated, and only seven patients experienced them. Six months after study enrollment, 10 patients in the intervention group and 6 patients in the control group had been infected with COVID-19, respectively. In the control group, ICU admission and mortality were observed, but in the intervention group, the infection was milder with no aggressive consequences. Conclusions: This study demonstrated the short-term safety and efficacy of tixagevimab–cilgavimab for COVID-19 preexposure prophylaxis in HD patients. These findings require more studies with more HD patients and longer follow-up periods.
Open AccessTixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study
Background and Objectives: In addition to a suboptimal and rapidly diminishing response to the coronavirus disease 2019 (COVID-19) vaccine, hemodialysis (HD) patients are at risk for developing a severe COVID-19 infection. In 2022, the combination of cilgavimab and tixagevimab (Evusheld, AstraZeneca) was approved for COVID-19 preexposure prophylaxis in high-risk groups. The purpose of this study was to evaluate the humoral response and short-term safety of this antibody combination in a group of HD patients. Materials and Methods: Seventy-three adult maintenance hemodialysis patients were recruited from a tertiary-care hospital for this double-blinded, non-randomized, placebo-controlled study. Patients were placed into two groups: the intervention group (n = 43) received a single 300 mg dosage of cilgavimab and tixagevimab, while the control group (n = 30) received a saline placebo. The titer of COVID-19-neutralizing antibodies was measured at baseline and after 1 and 6 months. The patients were evaluated for any drug-related adverse effects and monitored for six months for the emergence of any COVID-19-related events. Results: Patients in the intervention group were substantially older and had been on HD for longer (p = 0.002 and 0.006, respectively). The baseline antibody levels were higher in the Evusheld group. The antibody level in the intervention group increased significantly after 1 month and remained consistent for 6 months, whereas the antibody level in the control group fell significantly after 6 months during the study period (Wald χ2 = 30.620, p < 0.001). The drug-related adverse effects were modest and well-tolerated, and only seven patients experienced them. Six months after study enrollment, 10 patients in the intervention group and 6 patients in the control group had been infected with COVID-19, respectively. In the control group, ICU admission and mortality were observed, but in the intervention group, the infection was milder with no aggressive consequences. Conclusions: This study demonstrated the short-term safety and efficacy of tixagevimab–cilgavimab for COVID-19 preexposure prophylaxis in HD patients. These findings require more studies with more HD patients and longer follow-up periods.
- 1 June 2022
- Published by Mansoura University in Mansoura Medical Journal
- Vol. 51 (2) , 106-110
Serum level of Interleukin-33 and relation to disease activity in Juvenile Idiopathic Arthritis
Background The pathogenesis of juvenile idiopathic arthritis (JIA) is not fully understood. So, this study was conducted to investigate clinical usefulness of serum IL-33 levels as an indicator of disease activity in JIA. Methods This cross-sectional study was conducted on 45 JIA patients. All patients were subjected to detailed history taking, full clinical examination with emphasis on pattern and distribution of articular and extra-articular involvement. Juvenile arthritis disease activity score (JADAS28) was assessed. Venous blood (10 ml) was collected to assess routine laboratory investigations in addition to IL-33. Results Most of patients had sudden arthritis onset (64.4%) and (95.6%) had progressive course. Most of patients (64.4%) had general sites of distribution. 88.9% had emotional aggravation factor, while 86.7% had medication and movement as relieving factors. Only 8.9% of patients’ diseases are controlled, 46.7% had relapse, and 6.7% stopped treatment. 66.7% of patients had good response and 33.3% had poor response. JIA patients had a significantly higher serum IL-33 levels compared to IL-33 serum in the control group (p=0.008). There were significant positive correlation between IL-33 with duration of disease (p=0.002, r=0.612), DAS28CRP (p < 0.001, r=0.705) and DAS28ESR (p=0.001, r=0.667), However, serum IL- 33 levels did not significantly correlate with the levels of serum CRP or ESR. Conclusions JIA patients have significantly elevated IL-33 serum concentrations and that considerably correlated with clinical, laboratory and activity parameters of disease suggesting that it could be a valuable marker of JIA disease activity.
- 1 June 2022
- Published by Mansoura University in Mansoura Medical Journal
- Vol. 51 (2) , 106-110
Serum level of Interleukin-33 and relation to disease activity in Juvenile Idiopathic Arthritis
Background The pathogenesis of juvenile idiopathic arthritis (JIA) is not fully understood. So, this study was conducted to investigate clinical usefulness of serum IL-33 levels as an indicator of disease activity in JIA. Methods This cross-sectional study was conducted on 45 JIA patients. All patients were subjected to detailed history taking, full clinical examination with emphasis on pattern and distribution of articular and extra-articular involvement. Juvenile arthritis disease activity score (JADAS28) was assessed. Venous blood (10 ml) was collected to assess routine laboratory investigations in addition to IL-33. Results Most of patients had sudden arthritis onset (64.4%) and (95.6%) had progressive course. Most of patients (64.4%) had general sites of distribution. 88.9% had emotional aggravation factor, while 86.7% had medication and movement as relieving factors. Only 8.9% of patients’ diseases are controlled, 46.7% had relapse, and 6.7% stopped treatment. 66.7% of patients had good response and 33.3% had poor response. JIA patients had a significantly higher serum IL-33 levels compared to IL-33 serum in the control group (p=0.008). There were significant positive correlation between IL-33 with duration of disease (p=0.002, r=0.612), DAS28CRP (p < 0.001, r=0.705) and DAS28ESR (p=0.001, r=0.667), However, serum IL- 33 levels did not significantly correlate with the levels of serum CRP or ESR. Conclusions JIA patients have significantly elevated IL-33 serum concentrations and that considerably correlated with clinical, laboratory and activity parameters of disease suggesting that it could be a valuable marker of JIA disease activity.